Polymorphisms of cell cycle regulator genes CCND1 G870A and TP53 C215G: Association with colorectal cancer susceptibility risk in a Malaysian population

Zahary,Mohd  Nizam; Ahmad Aizat,Abdul  Aziz; Kaur,Gurjeet; Yeong Yeh,Lee; Mazuwin,Maya; Ankathil,Ravindran

doi:10.3892/ol.2015.3728

Polymorphisms of cell cycle regulator genes CCND1 G870A and TP53 C215G: Association with colorectal cancer susceptibility risk in a Malaysian population

Authors:
- Mohd Nizam Zahary
- Abdul Aziz Ahmad Aizat
- Gurjeet Kaur
- Lee Yeong Yeh
- Maya Mazuwin
- Ravindran Ankathil
View Affiliations

Affiliations: Human Genome Centre, School of Medical Sciences, University of Science Malaysia Health Campus, Kubang Kerian, Kelantan 16150, Malaysia, Institute for Research in Molecular Medicine, University of Science Malaysia, Minden, Penang 11800, Malaysia, Department of Medicine, School of Medical Sciences, University of Science Malaysia Health Campus, Kubang Kerian, Kelantan 16150, Malaysia, Department of Surgery, School of Medical Sciences, University of Science Malaysia Health Campus, Kubang Kerian, Kelantan 16150, Malaysia
Published online on: September 18, 2015 https://doi.org/10.3892/ol.2015.3728
Pages: 3216-3222

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) occurs as a more common sporadic form and a less common familial form. Our earlier analysis of germline mutations of mismatch repair genes confirmed only 32% of familial CRC cases as Lynch syndrome cases. It was hypothesized that the remaining familial aggregation may be ‘polygenic’ due to single nucleotide polymorphisms (SNPs) of low penetrance genes involved in cancer predisposition pathways, such as cell cycle regulation and apoptosis pathways. The current case‑control study involving 104 CRC patients (52 sporadic and 52 familial) and 104 normal healthy controls investigated the contribution of the SNPs cyclin D1 (CCND1) G870A and tumor protein p53 (TP53) C215G in modulating familial and sporadic CRC susceptibility risk. DNA was extracted from peripheral blood and the polymorphisms were genotyped by employing a polymerase chain reaction‑restriction fragment length polymorphism method. The association between these polymorphisms and CRC susceptibility risk was calculated using a binary logistic regression analysis and deriving odds ratios (ORs). The A/A variant genotype of CCND1 and G/G variant genotype of TP53 exhibited a significantly greater association with the risk of sporadic CRC [CCND1: OR, 3.471; 95% confidence interval (CI), 1.443‑8.350; P=0.005. TP53: OR, 2.829; CI, 1.119‑7.152; P=0.026] as well as familial CRC susceptibility (CCND1: OR, 3.086; CI, 1.270‑7.497; P=0.019. TP53: OR, 3.048; CI, 1.147‑8.097; P=0.030). The results suggest a potential role of the SNPs CCND1 G870A and TP53 C215G in the modulation of sporadic and familial CRC susceptibility risk.

View Figures

View References

1	Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 (Internet). International Agency for Research on Cancer (Lyon, France). 2013.Available from. http://globocan.iarc.frAccessed. July 27–2015
2	Goh KL, Quek KF, Yeo GT, Hilmi IN, Lee CK, Hasnida N, Aznan M, Kwan KL and Ong KT: Colorectal cancer in Asians: A demographic and anatomic survey in Malaysian patients undergoing colonoscopy. Aliment Pharmacol Ther. 22:859–864. 2005. View Article : Google Scholar : PubMed/NCBI
3	National Cancer Registry: Malaysia Cancer Statistics - Data and Figure: Peninsular Malaysia 2006. Kuala Lumpur: National Cancer Registry, Ministry of Health Malaysia. 2006.
4	Zahary MN, Kaur G, Hassan MR, Sidek AS, Singh H, Yeh LY and Ankathil R: Germline mutation and protein expression analysis of mismatch repair genes MSH6 and PMS2 in Malaysian Lynch syndrome patients. Int J Colorectal Dis. 29:261–262. 2014. View Article : Google Scholar : PubMed/NCBI
5	Sherr CJ: Cancer cell cycles. Science. 274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
6	Donnellan R and Chetty R: Cyclin D1 and human neoplasia. Mol Pathol. 51:1–7. 1998. View Article : Google Scholar : PubMed/NCBI
7	Zheng Y, Shen H, Sturgis EM, Wang LE, Eicher SA, Strom SS, Frazier ML, Spitz MR and Wei Q: Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: A case-control study. Carcinogenesis. 22:1195–1199. 2001. View Article : Google Scholar : PubMed/NCBI
8	Porter TR, Richards FM, Houlston RS, Evans DG, Jankowski JA, Macdonald F, Norbury G, Payne SJ, Fisher SA, Tomlinson I and Maher ER: Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene. 21:1928–1933. 2002. View Article : Google Scholar : PubMed/NCBI
9	Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y, Kakinuma H, Sato K, Nakamura A, Ogawa O and Kato T: Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 23:257–264. 2002. View Article : Google Scholar : PubMed/NCBI
10	Wang L, Habuchi T, Mitsumori K, Li Z, Kamoto T, Kinoshita H, Tsuchiya N, Sato K, Ohyama C, Nakamura A, et al: Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer. 103:116–120. 2003. View Article : Google Scholar : PubMed/NCBI
11	Lane DP: Cancer. p53, guardian of the genome. Nature. 358:15–16. 1992. View Article : Google Scholar : PubMed/NCBI
12	Levine AJ: p53, the cellular gatekeeper for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
13	Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X and Crook T: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 23:3328–3337. 2004. View Article : Google Scholar : PubMed/NCBI
14	Hong Y, Eu KW, Seow-Choen F, Fook-Chong S and Cheah PY: GG genotype of cyclin D1 G870A polymorphism is associated with increased risk and advanced colorectal cancer in patients in Singapore. Eur J Cancer. 41:1037–1044. 2005. View Article : Google Scholar : PubMed/NCBI
15	Cao Z, Song JH, Park YK, Maeng EJ, Nam SW, Lee JY and Park WS: The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma. 56:114–118. 2009. View Article : Google Scholar : PubMed/NCBI
16	Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar : PubMed/NCBI
17	Tárraga López PJ, Albero JS and Rodríguez-Montes JA: Primary and secondary prevention of colorectal cancer. Clin Med Insights Gastroenterol. 7:33–46. 2014. View Article : Google Scholar : PubMed/NCBI
18	Marin JJ, de Medina Sanchez F, Castaño B, Bujanda L, Romero MR, Martinez-Augustin O, Moral-Avila RD and Briz O: Chemoprevention, chemotherapy and chemoresistance in colorectal cancer. Drug Metab Rev. 44:148–172. 2012. View Article : Google Scholar : PubMed/NCBI
19	Sengupta N, Gill KA, MacFie TS, Lai CS, Suraweera N, Mcdonald S and Silver A: Management of colorectal cancer: A role for genetics in prevention and treatment? Pathol Res Pract. 204:469–477. 2008. View Article : Google Scholar : PubMed/NCBI
20	Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S and Couture J: Molecular biology of colorectal cancer. Curr Probl Cancer. 21:233–300. 1997. View Article : Google Scholar : PubMed/NCBI
21	Bellacosa A: Genetic hits and mutation rate in colorectal tumorigenesis: Versatility of Knudson's theory and implications for cancer prevention. Genes Chromosomes Cancer. 38:382–388. 2003. View Article : Google Scholar : PubMed/NCBI
22	Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R and Ben-Ze'ev A: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 96:5522–5527. 1999. View Article : Google Scholar : PubMed/NCBI
23	Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD and Heighway J: Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 11:1005–1011. 1995.PubMed/NCBI
24	Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ and Knudsen ES: Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation and cellular transformation. J Biol Chem. 278:30339–30347. 2003. View Article : Google Scholar : PubMed/NCBI
25	Sawa H, Ohshima TA, Ukita H, Murakami H, Chiba Y, Kamada H, Hara M and Saito I: Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene. 16:1701–1712. 1998. View Article : Google Scholar : PubMed/NCBI
26	Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI
27	Whibley C, Pharoah PD and Hollstein M: p53 polymorphisms: Cancer implications. Nat Rev Cancer. 9:95–107. 2009. View Article : Google Scholar : PubMed/NCBI
28	Thomas M, Kalita A, Labrecque S, Pim D, Banks L and Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 19:1092–1100. 1999.PubMed/NCBI
29	Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, et al: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 3:387–402. 2003. View Article : Google Scholar : PubMed/NCBI
30	Pim D and Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 108:196–199. 2004. View Article : Google Scholar : PubMed/NCBI
31	Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, et al: A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 25:47–54. 2000. View Article : Google Scholar : PubMed/NCBI
32	Zhang LQ, Wang J, Shang JQ, Bai JL, Liu FY, Guan X and Zhou JN: Cyclin D1 G870A polymorphism and colorectal cancer susceptibility: A meta-analysis of 20 populations. Int J Colorectal Dis. 26:1249–1255. 2011. View Article : Google Scholar : PubMed/NCBI
33	Yang Y, Wang F, Shi C, Zou Y, Qin H and Ma Y: Cyclin D1 G870A polymorphism contributes to colorectal cancer susceptibility: Evidence from a sytematic review of 22 case-control studies. PLoS One. 7:e368132012. View Article : Google Scholar : PubMed/NCBI
34	Sameer AS, Parray FQ, Dar MA, Nissar S, Banday MZ, Rasool S, Gulzar GM, Chowdri NA and Siddiqi MA: Cyclin D1 G870A polymorphism and risk of colorectal cancer: A case control study. Mol Med Rep. 7:811–815. 2013.PubMed/NCBI
35	Jiang J, Wang J, Suzuki S, Gajalakshmi V, Kuriki K, Zhao Y, Nakamura S, Akasaka S, Ishikawa H and Tokudome S: Elevated risk of colorectal cancer associated with the AA genotype of the cyclin D1 A870G polymorphism in an Indian population. J Cancer Res Clin Oncol. 132:193–199. 2006. View Article : Google Scholar : PubMed/NCBI
36	Sameer AS, Shah ZA, Syeed N, Banday MZ, Bashir SM, Bhat BA and Siddiqi MA: TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population. Genet Mol Res. 9:651–660. 2010. View Article : Google Scholar : PubMed/NCBI
37	Joshi AM, Budhathoki S, Ohnaka K, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, et al: TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: The Fukuoka Colorectal Cancer Study. Jpn J Clin Oncol. 41:232–238. 2011. View Article : Google Scholar : PubMed/NCBI
38	Song HR, Kweon SS, Kim HN, Piao JM, Yun WJ, Choi JS, Hwang JE, Yoon JY, Kim HR, Park YK, et al: p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer. 14:242–248. 2011. View Article : Google Scholar : PubMed/NCBI
39	Zhang Y, Liu L, Tang Y, et al: Polymorphisms in TP53 and MDM2 contribute to higher risk of colorectal cancer in Chinese population: A hospital-based, case control study. Mol Biol Rep. 39:9661–9668. 2012. View Article : Google Scholar : PubMed/NCBI
40	Aizat AA, Shahpudin SN, Mustapha MA, et al: Association of Arg72Pro of P53 polymorphism with colorectal cancer susceptibility risk in Malaysian population. Asian Paci J Cancer Prev. 12:2909–2913. 2011.
41	Economopoulos KP, Sergentanis TN, Zagouri F and Zografos GC: Association between p53 Arg72Pro polymorphism and colorectal cancer risk: A meta-analysis. Onkologie. 33:666–674. 2010. View Article : Google Scholar : PubMed/NCBI
42	Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V and Murray S: TP53 Arg72Pro polymorphism and colorectal cancer risk: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 19:1840–1847. 2010. View Article : Google Scholar : PubMed/NCBI
43	Oh J, Kim JW, Lee BE, Jang MJ, Chong SY, Park PW, Hwang SG, Oh D and Kim NK: Polymorphisms of the pri-miR-34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer. Oncol Rep. 31:995–1002. 2014.PubMed/NCBI
44	Chen J, Etzel CJ, Amos CI, Zhang Q, Viscofsky N, Lindor NM, Lynch PM and Frazier ML: Genetic variant in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome. Cancer Causes Control. 20:1769–1777. 2009. View Article : Google Scholar : PubMed/NCBI
45	Krüger S, Bier A, Engel C, Mangold E, Pagenstecher C, von Knebel Doeberitz M, Holinski-Feder E, Moeslein G, Schulmann K, Plaschke J, et al: The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC). J Med Genet. 42:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
46	Sotamaa K, Liyanarachchi S, Mecklin JP, Järvinen H, Aaltonen LA, Peltomäki P and de la Chapelle A: p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res. 11:6840–6844. 2005. View Article : Google Scholar : PubMed/NCBI
47	Krüger S, Engel C, Bier A, Mangold E, Pagenstecher C, Doeberitz MV, Holinski-Feder E, Moeslein G, Keller G, Kunstmann E, et al: Absence of association between cyclin D1 (CCND1) G870A polymorphism and age of onset in hereditary nonpolyposis colorectal cancer. Cancer Lett. 236:191–197. 2006. View Article : Google Scholar : PubMed/NCBI
48	Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J and Scott RJ: MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer. 120:563–565. 2007. View Article : Google Scholar : PubMed/NCBI